Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.52
    -1.00 (-0.92%)

    Market Cap: $187.95B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Abbott Laboratories (ABT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Abbott Laboratories (ABT) to earn $5.52 per share in the fiscal year ending Dec 31, 2026, on revenue of $49.95B. Of 28 analysts, 23 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 10 estimates for the fiscal year ending Dec 31, 2026 were revised up and 13 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.

    RatingAnalystsShare
    Strong Buy517.9%
    Buy1864.3%
    Hold517.9%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 7.6% and revenue estimates rise 7.1%.

    Fiscal year ending Dec 31, 2026
    $5.52
    EPS consensus, revenue $49.95B
    Fiscal year ending Dec 31, 2027
    $5.94
    EPS consensus, revenue $53.50B
    Next report
    Jan 20, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$5.52$5.49 to $5.5427$49.95B$49.11B to $50.14B25
    Dec 31, 2027$5.94$5.89 to $6.0827$53.50B$51.42B to $54.77B27

    Quarterly Estimates

    The EPS consensus falls from $1.65 for the quarter ending Dec 31, 2026 to $1.23 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.65$1.60 to $1.7327$13.35B$12.88B to $14.05B27
    Mar 31, 2027$1.23$1.20 to $1.2818$12.57B$12.43B to $12.73B17

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 12 upward and 50 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 20261013
    Fiscal year ending Dec 31, 2027124
    Quarter ending Mar 31, 2027113

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$5.52$5.52$5.52$5.52$5.520.0%
    Fiscal year ending Dec 31, 2027$5.94$5.94$6.06$6.07$6.06-2.1%
    Quarter ending Mar 31, 2027$1.23$1.23$1.29$1.29$1.29-4.4%

    Frequently Asked Questions About ABT

    What is the ABT stock forecast?

    Consensus analyst estimates put Abbott Laboratories's EPS at $5.52 for the fiscal year ending Dec 31, 2026, on revenue of $49.95B. The consensus rating from 28 analysts is Buy.

    How do analysts rate ABT stock?

    Of 28 analysts covering Abbott Laboratories, 5 rate it Strong Buy, 18 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ABT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.52, with estimates from $5.49 to $5.54 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.94, with estimates from $5.89 to $6.08 from 27 analysts.

    What revenue do analysts expect from Abbott Laboratories next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $49.95B, with estimates from $49.11B to $50.14B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $53.50B, with estimates from $51.42B to $54.77B.

    How many analysts cover ABT?

    28 analysts rate Abbott Laboratories stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.